Form 4: Synaptogenix Director William S. Singer Acquires Stock Options

Director William S. Singer acquired stock options for 800 shares of Synaptogenix, Inc. at an exercise price of $2.28, vesting after one year of service.

Summary

• William S. Singer, a director of Synaptogenix, Inc., filed a Form 4 on April 7, 2025, reporting a transaction.
• On April 3, 2025, Singer acquired stock options for 800 shares of Synaptogenix common stock.
• The exercise price of the options is $2.28 per share.
• The options vest after one year of service following April 3, 2025, and expire on April 3, 2035.
• Following the transaction, Singer directly owns options for 800 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it is a standard disclosure of stock option grants. It doesn't inherently indicate positive or negative performance.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This allows investors to monitor the actions of those with the most knowledge of the company's prospects.

Comparison to Industry Standards

• Stock option grants to directors are a common form of compensation in publicly traded companies.
• The vesting schedule of one year is fairly standard.
• The specific terms of the option grant (number of shares, exercise price, vesting schedule) would need to be compared to similar companies in the biotechnology industry to assess its relative value.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding director compensation and potential future dilution.

Key Dates

Keywords

Synaptogenix, Director, Stock Options, Form 4, Beneficial Ownership, SNPX, Singer, Equity Securities